Evidence that CHIP may lead to misinterpretation of predictive ctDNA assays was recently reported in a study involving men with advanced prostate cancer who were undergoing plasma mutation testing for potential response to PARP inhibitors [94]. Here, STUB1 is linked to prostate carcinoma.